Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03421626 · ClinicalTrials.gov registry record
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)
A clinical trial, sponsored by Cepheid.
- Completed
- Registry status
- 266
- Enrollment target
NCT03421626 is a clinical trial that has completed, run by Cepheid. The registered enrollment target is 266 participants.
The verdict
NCT03421626 has completed, sponsored by Cepheid.
- COMPLETED
- Registry status
- 266 participants
- Enrollment target
Study Summary
The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Interventions
- DEVICE Xpert BCR-ABL Ultra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2018-08-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03421626
The ClinicalTrials.gov registry entry for NCT03421626 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cepheid, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xpert BCR-ABL Ultra is the first listed.
NCT03421626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03421626 about?
NCT03421626 is a clinical study titled "Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)". The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results...
What is the current status of trial NCT03421626?
This trial is currently completed. The enrollment target is 266 participants. The study started on 2017-11-08. Estimated completion is 2018-08-20.
What interventions are being tested in trial NCT03421626?
The interventions under investigation include: Xpert BCR-ABL Ultra (DEVICE).
Who is sponsoring clinical trial NCT03421626?
This trial is sponsored by Cepheid, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.